1. Home
  2. HOVR vs CINGW Comparison

HOVR vs CINGW Comparison

Compare HOVR & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HOVR
  • CINGW
  • Stock Information
  • Founded
  • HOVR 2013
  • CINGW N/A
  • Country
  • HOVR Canada
  • CINGW United States
  • Employees
  • HOVR N/A
  • CINGW 13
  • Industry
  • HOVR Blank Checks
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • HOVR Finance
  • CINGW Health Care
  • Exchange
  • HOVR Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • HOVR N/A
  • CINGW N/A
  • IPO Year
  • HOVR N/A
  • CINGW 2021
  • Fundamental
  • Price
  • HOVR $1.02
  • CINGW $0.05
  • Analyst Decision
  • HOVR Strong Buy
  • CINGW
  • Analyst Count
  • HOVR 1
  • CINGW 0
  • Target Price
  • HOVR $2.00
  • CINGW N/A
  • AVG Volume (30 Days)
  • HOVR 1.2M
  • CINGW N/A
  • Earning Date
  • HOVR 04-14-2025
  • CINGW N/A
  • Dividend Yield
  • HOVR N/A
  • CINGW N/A
  • EPS Growth
  • HOVR N/A
  • CINGW N/A
  • EPS
  • HOVR 0.29
  • CINGW N/A
  • Revenue
  • HOVR N/A
  • CINGW N/A
  • Revenue This Year
  • HOVR $0.39
  • CINGW N/A
  • Revenue Next Year
  • HOVR $196.92
  • CINGW N/A
  • P/E Ratio
  • HOVR $3.67
  • CINGW N/A
  • Revenue Growth
  • HOVR N/A
  • CINGW N/A
  • 52 Week Low
  • HOVR $0.24
  • CINGW N/A
  • 52 Week High
  • HOVR $1.63
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • HOVR 73.56
  • CINGW N/A
  • Support Level
  • HOVR $0.84
  • CINGW N/A
  • Resistance Level
  • HOVR $1.16
  • CINGW N/A
  • Average True Range (ATR)
  • HOVR 0.14
  • CINGW 0.00
  • MACD
  • HOVR 0.04
  • CINGW 0.00
  • Stochastic Oscillator
  • HOVR 85.21
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Share on Social Networks: